Novo Nordisk Chip Ganassi Racing Celebrates First IZOD IndyCar Series Win
Charlie Kimball Makes History as First Driver with Diabetes to Win an IndyCar Race
Plainsboro, NJ (August 6, 2013) /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, is pleased to announce that Charlie Kimball, driver of the No. 83 NovoLog® FlexPen® Honda, has become the first and only licensed driver with diabetes to win an IndyCar race. This milestone was achieved as the Novo Nordisk Chip Ganassi Racing Team saw its first-ever IndyCar Series victory, secured at the Honda Indy 200 at Mid-Ohio on Sunday.
“This victory means the world to me and it’s a dream come true, but I could never have done it alone,” said Kimball. “I’m so fortunate to have the support of Novo Nordisk, my team and my crew, all of whom have played a crucial role in getting me to where I am today with racing, managing my diabetes, and in securing this win.”
Kimball was first diagnosed with diabetes in 2007 during a routine physician’s visit. Along with diet, exercise and the support of his doctor and crew, Kimball uses NovoLog® FlexPen® (insulin aspart [rDNA origin] injection) to help manage his blood sugar before and after races.
Despite an earlier incident in Saturday’s practice session at the Mid-Ohio Sports Car Course, Kimball rebounded in qualifying, starting fifth and led a race-high 46 laps, including the last 18 laps after passing Simon Pagenaud to take the lead. This win follows a string of strong performances from Kimball in his third season with Novo Nordisk Chip Ganassi Racing, including five top-10 finishes and a second place podium finish in Long Pond, PA. This win moves Kimball ahead four positions in the IndyCar point standings where he is currently tied for seventh place.
“We are all extremely proud of Charlie for securing his first IndyCar Series victory over the weekend,” said Camille Lee, senior vice president, Diabetes Marketing at Novo Nordisk. “This momentous win is not only significant for Charlie professionally, but it also demonstrates to the diabetes community people living with diabetes can still pursue their dreams.”
There are five races remaining in the 2013 IZOD IndyCar Series, which ends on October 19. Now through September 15, fans still have a chance to cheer for Kimball in person through a contest inviting them to “join” the Race with Insulin® crew. By sharing Kimball’s story about the importance of team support, participants are eligible to win a three-day/two-night trip to the IndyCar World Championship in Fontana, CA.
Fans can enter by logging on to www.racewithinsulin.com/crew, visiting the Race with Insulin® exhibit in the IndyCar Fan Village at select IZOD IndyCar Series races, or via mail.*
Keep up with Charlie on Twitter by following him @racewithinsulin.
Please see updated Important Safety Information below, including use with thiazolidinediones (TZDs).
Indications and Usage
What is NovoLog® (insulin aspart [rDNA origin] injection)?
- NovoLog® is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
Important Safety Information
Who should not use NovoLog®?
- Do not use NovoLog® if your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients.
What should I tell my health care provider before taking NovoLog®?
- About all of your medical conditions, including liver, kidney, or heart problems.
- If you are pregnant, breastfeeding, or plan to do either.
- About all prescription and nonprescription medicines you take, including supplements, as your dose may need to change.
How should I take NovoLog® (insulin aspart [rDNA origin] injection)?
- Eat a meal within 5 to 10 minutes after using NovoLog®, a fast-acting insulin, to avoid low blood sugar. Do not inject NovoLog® if you do not plan to eat right after your injection or bolus pump infusion.
- Do not mix NovoLog® with any other insulin when used in a pump or with any insulin other than NPH when used with injections by syringe.
- Do not change your dose or type of insulin unless you are told to by your health care provider.
- Do not share needles, insulin pens, or syringes.
- Check your blood sugar levels as directed by your health care provider.
What should I consider while using NovoLog®?
- Alcohol, including beer and wine, may affect your blood sugar.
- Be careful when driving a car or operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar. Talk to your health care provider if you often have low blood sugar or no warning signs of low blood sugar.
What are the possible side effects of NovoLog®?
- Low blood sugar, including when too much is taken. Some symptoms include sweating, shakiness, confusion, and headache. Severe low blood sugar can cause unconsciousness, seizures, and death.
- Serious allergic reactions may occur. Get medical help right away, if you develop a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
- Other side effects include injection site reactions (like redness, swelling, and itching), skin thickening or pits at the injection site, swelling of your hands and feet, if taken with thiazolidinediones (TZDs) possible heart failure, vision changes, low potassium in your blood, and weight gain.
Please visit novolog.com for Prescribing Information.
*Certain restrictions apply. See official rules for entry information.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk-us.com or follow our news in the US on Twitter: @NovoNordiskUS.
In the United States, 25.8 million people have diabetesi, a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life.
i2011 National Diabetes Fact Sheet. Centers for Disease Control . http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed August 4, 2013.